Table 4.
Univariate and multivariate logistic regression response analysis to DLI treatment, n = 131.
| Univariate OR (95% CI) | p | Multivariate OR (95% CI) * | p | |
|---|---|---|---|---|
| Age at DLI1 >60 years, n = 38 | 0.94 (0.42–2.08) | 0.88 | ||
| Gender | ||||
| Female | 1 (ref) | - | ||
| Male (n = 76) | 0.82 (0.41–1.68) | 0.59 | ||
| Disease | 14.07 (4.05–59.57) | <0.0001 | ||
| Hodgkin Lymphoma | 2.12 (0.41–10.99) | 0.37 | ||
| Acute lymphoblastic leukaemia | 1.01 (0.29–3.45) | 0.99 | ||
| Acute myeloblastic leukaemia | 1 (ref) | - | ||
| Chronic lymphocytic leukaemia | 2.12 (0.41–10.99) | 0.37 | ||
| Chronic myeloid leukaemia | 2.83 (0.16–49.22) | 0.48 | ||
| Non-Hodgkin lymphoma | 11.28 (2.07–61.44) | <0.01 | ||
| Multiple myeloma | 1.67 (0.63–4.40) | 0.30 | ||
| Osteomyelofibrosis | 2.71 × 10−4 (3.59 × 10−91–2.04 × 1083) | 0.94 | ||
| Myelodysplasia | 8.46 (1.48–48.26) | 0.02 | ||
| Indication for DLI | ||||
| Pre-emptive | 1 (ref) | - | ||
| Relapse | 0.21 (0.09–0.45) | <0.0001 | 0.18 (0.07–0.45) | <0.001 |
| Associated treatment | ||||
| No | 1 (ref) | |||
| Yes | 0.59 (0.27–1.27) | 0.18 | ||
| Type of DLI | ||||
| Classical | 1 (ref) | - | ||
| gDLI | 1.56 (0.77–3.18) | 0.22 | ns | |
| Post DLI GvHD | 8.53 (3.01–26.78) | <0.0001 | ||
| No GvHD | 1 (ref) | |||
| GvHD not requiring treatment | 1.91 (0.78–4.69) | 0.16 | ||
| Treatment-requiring GvHD | 9.08 (3.28–25.14) | <0.0001 |
Abbreviations: DLI = donor lymphocyte infusion, gDLI = g-csf stimulated donor lymphocyte infusion, OR = odd ratio, CI = confidence interval, GvHD = graft versus host disease. * Multivariate model for indication comparing non-Hodgkin lymphoma and myelodysplasia vs. others, model for indication comparing relapse and pre-emptive situation vs. others and model for GvHD comparing treatment-requiring GvHD vs. others.